| Health / Medical Topics |
Anti-TGF-beta RII Monoclonal Antibody IMC-TR1
A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression. (NCI Thesaurus)
YOU MAY ALSO LIKE
A monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory…
An antibody-drug conjugate (ADC) comprised of a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to…
A recombinant human-mouse chimeric monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal…
A humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), with potential antineoplastic activity. Anti-TA-MUC1 monoclonal antibody PankoMab targets and binds…
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic…
The determination of the amount of anti-single stranded DNA IgG present in a sample.
